ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update
03 Agosto 2023 - 3:05PM
ReShape Lifesciences Inc. (Nasdaq:
RSLS), the premier physician-led weight loss and metabolic
health-solutions company, today announced that it will report its
financial results for the second quarter ended June 30, 2023,
including a corporate update on Monday, August 7, 2023, after
market. Management will host a conference call at 5:00 pm ET the
same day and will be joined by a member of ReShape’s Scientific
Advisory Board, Christine Ren-Fielding, M.D., Professor of Surgery
at NYU Grossman School of Medicine, Director of the NYU Langone
Weight Management Program and Chief of the Division of Bariatric
Surgery.
A live webcast will be available on the “Events
and Presentations” section of ReShape’s website at:
https://ir.reshapelifesciences.com/events-and-presentations. To
access the call by phone, please register with the following
Registration Link, and dial-in details will be provided.
Participants using this feature are requested to dial into the
conference call fifteen minutes ahead of time to avoid delays.
An archived replay will be available on the
“Events and Presentations” section of ReShape’s website at:
https://ir.reshapelifesciences.com/events-and-presentations.
About ReShape
Lifesciences®ReShape Lifesciences® is America’s premier
weight loss and metabolic health-solutions company, offering an
integrated portfolio of proven products and services that manage
and treat obesity and metabolic disease. The FDA-approved Lap-Band®
System provides minimally invasive, long-term treatment of obesity
and is an alternative to more invasive surgical stapling procedures
such as the gastric bypass or sleeve gastrectomy. ReShapeCare™ is a
virtual weight-management program that supports lifestyle changes
for all weight loss patients led by board-certified health coaches
to help them keep the weight off over time. ReShape Marketplace™ is
an online collection of quality wellness products curated for all
consumers to help them achieve their health goals. The
investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system
utilizes a proprietary vagus nerve block and stimulation technology
platform for the treatment of Type 2 diabetes and metabolic
disorders. The Obalon® balloon technology is a non-surgical,
swallowable, gas-filled intra-gastric balloon that is designed to
provide long-lasting weight loss. For more information, please
visit www.reshapelifesciences.com.
CONTACTS:Company
Contact:Thomas StankovichChief Financial
Officer949-276-6042ir@ReShapeLifesci.com
Investor Relations Contact:Rx
Communications GroupMichael
Miller(917)-633-6086mmiller@rxir.com
ReShape Lifesciences (NASDAQ:RSLS)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
ReShape Lifesciences (NASDAQ:RSLS)
Gráfica de Acción Histórica
De May 2023 a May 2024